Feldan News

Seoul (South Korea) & Québec City (Canada) June 27, 2018 – GC LabCell (hereafter “GCLC”) and Feldan Therapeutics (hereafter “Feldan”) announced an agreement today granting GCLC exclusive rights to use …

Our CEO François-Thomas Michaud and Strategic development director Vincent Menard are pleased to be in Boston this week for the BIO convention. They are looking forward to meeting with international …

QUEBEC CITY, May 29, 2018 - Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform. This technology, a peptide-based …

Feldan Therapeutics’ Research Director, Dr. David Guay, will be attending TIDES: Oligonucleotides and Peptide Therapeutics Conference next week, May 7-10th at Hynes Convention Center in Boston. Come to chat with …

Our CEO Francois-Thomas Michaud and Strategic Alliance Director, Vincent Ménard, MBA Ph.D. will be attending RESI2018 conference in Toronto, April 10th. Come and meet with them to discuss how Feldan …

Read the new article on the Feldan Shuttle Technology published in PLOS One (April 2018) : http://journalsplosorg/plosone/article?id=101371/journalpone0195558 …

QUÉBEC city, March 29, 2018 – CQDM is pleased to announce the selection of a new Quantum Leap project jointly with Feldan Therapeutics for a total amount of $1.2M. The …

Feldan Therapeutics will be attending the Innate Killer Summit from March 27 to 29 in San Diego, CA, USA. Come and meet with our Business Development Director Meriem Benchabane and …

Read the new article on the Feldan Shuttle Technology published in Drug Development & Delivery edition on January 2018. download article : wwwdrug-devcom/Uploads/Public/January%202018%20WEBpdf …

Combined Feldan Shuttle and Green Cross LabCell NK cell technologies will be used to develop hyperactive NK cell immunotherapies QUEBEC, Jan. 15, 2018 /CNW Telbec/ - Green Cross LabCell, involved …